Literature DB >> 1826836

Intrapulmonary interleukin 1 mediates acute immune complex alveolitis in the rat.

J S Warren1.   

Abstract

Interleukin 1 alpha and beta are polypeptide cytokines that possesses a wide variety of immunologic and inflammatory activities. We have examined the role of intrapulmonary interleukin 1 in the pathogenesis of acute IgG immune complex alveolitis in the rat. Intratracheal instillation of IgG anti-bovine serum albumin accompanied by intravenous infusion of bovine albumin results in acute neutrophil and complement-dependent alveolitis. Over the course of evolving lung injury there was a 12-fold increase in bronchoalveolar lavage fluid interleukin 1 activity. Intratracheal instillation of neutralizing anti-interleukin 1 beta antibodies upon induction of lung injury resulted in a dose-dependent reduction in lung injury as assessed by measurements of pulmonary hemorrhage and vascular permeability. Morphometric analysis and measurements of myeloperoxidase activities in whole lung homogenates from rats that received anti-interleukin 1 beta revealed a pronounced reduction in neutrophil recruitment compared to positive controls. Incubation of isolated alveolar macrophages with preformed IgG immune complexes resulted in dose-dependent interleukin 1 secretion. These data suggest that intrapulmonary IL-1 activity plays a role in neutrophil recruitment and is necessary for the full development of acute IgG immune complex induced lung injury in the rat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826836     DOI: 10.1016/0006-291x(91)91608-f

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  New insights into mechanisms of oxyradical and neutrophil mediated lung injury.

Authors:  P A Ward; M S Mulligan
Journal:  Klin Wochenschr       Date:  1991-12-15

2.  NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement.

Authors:  A B Lentsch; B J Czermak; N M Bless; P A Ward
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 3.  Endogenous regulation of the acute inflammatory response.

Authors:  Peter A Ward; Alex B Lentsch
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

4.  Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury.

Authors:  A Seekamp; J S Warren; D G Remick; G O Till; P A Ward
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

5.  Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1.

Authors:  M S Mulligan; A A Vaporciyan; M Miyasaka; T Tamatani; P A Ward
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

6.  In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13.

Authors:  A B Lentsch; T P Shanley; V Sarma; P A Ward
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

7.  Regulatory roles of tumor necrosis factor-alpha and interleukin-1 beta in monocyte chemoattractant protein-1-mediated pulmonary granuloma formation in the rat.

Authors:  C M Flory; M L Jones; B F Miller; J S Warren
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

8.  Pulmonary expression of ICAM-1 and LFA-1 in experimental Goodpasture's syndrome.

Authors:  P A Hill; H Y Lan; D J Nikolic-Paterson; R C Atkins
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Relationship between interleukin-1 beta and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat.

Authors:  J S Warren
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

10.  Requirements for leukocyte adhesion molecules in nephrotoxic nephritis.

Authors:  M S Mulligan; K J Johnson; R F Todd; T B Issekutz; M Miyasaka; T Tamatani; C W Smith; D C Anderson; P A Ward
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.